The UK and US have concluded a key commercial pact that will keep no tariffs on UK medicine exports being sold in the American market.
Key Provisions of the Pact
Under the terms of the agreement, the UK has agreed to boost spending on medicines through the NHS. This move ensures that import taxes on these vital goods will stay at nothing for a period of the next three years.
This development follows previous warnings to dramatically increase tariffs on branded drug products, with potential rates mentioned up to one hundred percent.
"This agreement with the United Kingdom strengthens the international landscape for new treatments and brings much-needed equity to U.S.–U.K. pharmaceutical trade," an announcement noted.
Commercial Significance
Drugs represent one of the Britain's biggest export categories to the United States, which is easily the primary destination for leading UK drugmakers.
Trade data reveal that in the year prior to the third quarter, the UK exported pharmaceutical products worth £11.1bn to the US. This amount made up nearly one-fifth of total UK exports in that timeframe.
"This guarantee secures jobs, increases capital expenditure and sets the stage for the UK to emerge as a global hub for life sciences," a government official stated.
Specific UK Commitments
The agreement includes several key commitments from the UK:
- Revised Affordability Limit: The UK will raise the affordability limit at which it deems new medicines to be prohibitively costly by 25%.
- Higher Drug Budget: There is a aim to increase overall NHS spending on drugs from 0.3 percent of GDP to 0.6% over the following ten-year period.
- Refund Ceiling: The sum manufacturers must refund to the NHS to control costs will be limited at fifteen percent. In the past, refunds topped 20%.
Industry Background
The pact follows a protracted dispute between the sector and the ministers over spending levels and approval rates.
This friction were exacerbated by arguments that US consumers were paying several times more for the identical medicines than consumers in the UK and Europe.
Recently, several major manufacturing plans in the UK have been halted or cancelled, while major investments have been pledged toward American operations.
The Science Minister stated that the NHS had to increase expenditure on drugs, noting that its spending on drugs had decreased as a share of its overall budget over the past decade.
